Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
945 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03725059 | Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) | active not recruiting | Phase 3 | 1,240 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Jul 11, 2025 | clinicaltrials |
| NCT01757535 | Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission(QUAZAR AML-001) | completed | Phase 3 | 472 | Celgene |
| 23 |
| Jul 8, 2025 |
| clinicaltrials |
| NCT01776840 | A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 523 | Janssen Research & Development, LLCINDUSTRY | 28 | Jul 8, 2025 | clinicaltrials |
| NCT05751928 | A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma(NEO-MIMAJOR) | active not recruiting | Phase 3 | 411 | BiocadINDUSTRY | 2 | Jul 8, 2025 | clinicaltrials |
| NCT06640530 | Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin(UNIVERSE) | active not recruiting | Phase 3 | 392 | BiocadINDUSTRY | 3 | Jul 8, 2025 | clinicaltrials |
| NCT03522246 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy(ATHENA) | active not recruiting | Phase 3 | 1,097 | pharmaand GmbHINDUSTRY | 24 | Jun 24, 2025 | clinicaltrials |
| NCT06434077 | Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer | not yet recruiting | Phase 3 | 60 | S.LAB (SOLOWAYS)OTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT00981058 | First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin(SQUIRE) | completed | Phase 3 | 1,093 | Eli Lilly and CompanyINDUSTRY | 26 | Jun 18, 2025 | clinicaltrials |
| NCT02667587 | An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)(CheckMate548) | completed | Phase 3 | 716 | Bristol-Myers SquibbINDUSTRY | 19 | Jun 18, 2025 | clinicaltrials |
| NCT04100018 | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer(CheckMate 7DX) | completed | Phase 3 | 1,030 | Bristol-Myers SquibbINDUSTRY | 28 | Jun 12, 2025 | clinicaltrials |
| NCT03800134 | A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer(AEGEAN) | active not recruiting | Phase 3 | 825 | AstraZenecaINDUSTRY | 28 | Jun 11, 2025 | clinicaltrials |
| NCT03072238 | Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer(IPATential150) | completed | Phase 3 | 1,101 | Hoffmann-La RocheINDUSTRY | 26 | Jun 6, 2025 | clinicaltrials |
| NCT03390686 | A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients | active not recruiting | Phase 3 | 650 | Prestige Biopharma LimitedINDUSTRY | 17 | May 31, 2025 | clinicaltrials |
| NCT01974440 | A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma(SELENE) | completed | Phase 3 | 403 | Janssen Research & Development, LLCINDUSTRY | 19 | May 25, 2025 | clinicaltrials |
| NCT01844505 | Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) | completed | Phase 3 | 945 | Bristol-Myers SquibbINDUSTRY | 22 | May 21, 2025 | clinicaltrials |
| NCT02577406 | An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation(IDHENTIFY) | completed | Phase 3 | 319 | CelgeneINDUSTRY | 18 | May 18, 2025 | clinicaltrials |
| NCT03834519 | Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)(KEYLYNK-010) | completed | Phase 3 | 793 | Merck Sharp & Dohme LLCINDUSTRY | 20 | May 18, 2025 | clinicaltrials |
| NCT04427072 | Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation(GeoMETry-III) | terminated | Phase 3 | 22 | Novartis PharmaceuticalsINDUSTRY | 18 | May 16, 2025 | clinicaltrials |
| NCT03158688 | Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.(CANDOR) | completed | Phase 3 | 466 | AmgenINDUSTRY | 19 | May 9, 2025 | clinicaltrials |
| NCT03562637 | Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC | active not recruiting | Phase 3 | 575 | OBI Pharma, IncINDUSTRY | 13 | May 9, 2025 | clinicaltrials |
| NCT02076009 | A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 569 | Janssen Research & Development, LLCINDUSTRY | 18 | May 1, 2025 | clinicaltrials |
| NCT03277105 | A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 522 | Janssen Research & Development, LLCINDUSTRY | 18 | Apr 29, 2025 | clinicaltrials |
| NCT03551626 | Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes(COMBI-APlus) | completed | Phase 3 | 552 | Novartis PharmaceuticalsINDUSTRY | 23 | Apr 29, 2025 | clinicaltrials |
| NCT01853826 | An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s) | completed | Phase 3 | 481 | Boehringer IngelheimINDUSTRY | 11 | Apr 11, 2025 | clinicaltrials |
| NCT02288247 | A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone(PRESIDE) | completed | Phase 3 | 688 | Astellas Pharma Europe Ltd.INDUSTRY | 16 | Apr 8, 2025 | clinicaltrials |
| NCT03257267 | Study of Cemiplimab in Adults With Cervical Cancer | completed | Phase 3 | 608 | Regeneron PharmaceuticalsINDUSTRY | 14 | Apr 8, 2025 | clinicaltrials |
| NCT04786964 | Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC(CONTERNO) | terminated | Phase 3 | 25 | Checkpoint Therapeutics, Inc.INDUSTRY | 8 | Apr 2, 2025 | clinicaltrials |
| NCT03635983 | A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma | completed | Phase 3 | 783 | Bristol-Myers SquibbINDUSTRY | 27 | Apr 1, 2025 | clinicaltrials |
| NCT00490139 | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D(ALTTO) | completed | Phase 3 | 8,381 | Novartis PharmaceuticalsINDUSTRY | 44 | Mar 21, 2025 | clinicaltrials |
| NCT00667251 | Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer | completed | Phase 3 | 652 | Novartis PharmaceuticalsINDUSTRY | 21 | Mar 21, 2025 | clinicaltrials |
| NCT01160211 | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | completed | Phase 3 | 369 | Novartis PharmaceuticalsINDUSTRY | 29 | Mar 7, 2025 | clinicaltrials |
| NCT01958021 | Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer(MONALEESA-2) | completed | Phase 3 | 668 | Novartis PharmaceuticalsINDUSTRY | 29 | Mar 7, 2025 | clinicaltrials |
| NCT04963270 | A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis | terminated | Phase 3 | 188 | Hoffmann-La RocheINDUSTRY | 17 | Feb 28, 2025 | clinicaltrials |
| NCT05732805 | A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma(OCTAVA) | active not recruiting | Phase 3 | 270 | BiocadINDUSTRY | 3 | Feb 27, 2025 | clinicaltrials |
| NCT06845306 | The Use of Indocyanine Green Near-infrared Fluorescence for Bowel Perfusion Quantitative Assessment in Order to Prevent Anastomotic Leakage in Colorectal Surgery(ICG-NIRF) | not yet recruiting | Phase 3 | 1,268 | Vadim KuznetsovNETWORK | 1 | Feb 25, 2025 | clinicaltrials |
| NCT02807636 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma(IMvigor130) | completed | Phase 3 | 1,213 | Hoffmann-La RocheINDUSTRY | 35 | Feb 24, 2025 | clinicaltrials |
| NCT03088813 | Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer(RESILIENT) | completed | Phase 3 | 491 | IpsenINDUSTRY | 18 | Feb 19, 2025 | clinicaltrials |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 3 | 743 | Bristol-Myers SquibbINDUSTRY | 22 | Feb 17, 2025 | clinicaltrials |
| NCT02437318 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.(SOLAR-1) | completed | Phase 3 | 572 | Novartis PharmaceuticalsINDUSTRY | 31 | Feb 13, 2025 | clinicaltrials |
| NCT03358875 | Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)(RATIONALE-303) | completed | Phase 3 | 805 | BeiGeneINDUSTRY | 10 | Feb 10, 2025 | clinicaltrials |
| NCT01828112 | LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | completed | Phase 3 | 231 | Novartis PharmaceuticalsINDUSTRY | 20 | Feb 7, 2025 | clinicaltrials |
| NCT01715285 | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | completed | Phase 3 | 1,209 | Janssen Research & Development, LLCINDUSTRY | 33 | Feb 4, 2025 | clinicaltrials |
| NCT01855750 | A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | completed | Phase 3 | 838 | Janssen Research & Development, LLCINDUSTRY | 27 | Feb 4, 2025 | clinicaltrials |
| NCT03796858 | A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy(COSMOS) | completed | Phase 3 | 285 | Janssen Pharmaceutica N.V., BelgiumINDUSTRY | 14 | Feb 3, 2025 | clinicaltrials |
| NCT02576574 | Avelumab in First-line NSCLC (JAVELIN Lung 100) | completed | Phase 3 | 1,214 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 42 | Jan 31, 2025 | clinicaltrials |
| NCT02990338 | Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients(ICARIA-MM) | completed | Phase 3 | 307 | SanofiINDUSTRY | 24 | Jan 17, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials